N/A (healthy adults)
Conditions
Interventions
Pyrroloquinoline quinone disodium salt-containing food, 4 weeks excessive consumption
Sponsors
Oneness support Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Healthy adult males and females between the ages of 40 and less than 80 (2)Those with a BMI of less than 30 (3)Those whose written informed consent have been obtained
Exclusion criteria
Exclusion criteria: (1)Those with a history of hepatic disease, renal disease, gastrointestinal disease, etc., or any other disease that may affect the results of this study, or those with a history of surgery (2)Those who have undergone hospitalization for treatment due to stroke, subarachnoid hemorrhage, cerebral infarction, cerebral hemorrhage, cerebral contusion, or head trauma (3)Those with abnormal liver and renal function test values (4)Those who have a disease currently being treated (5)Those with food and drug allergies (6)Those with anemia (7)Previous experience of poor or worsened health after giving a blood sample (8)Blood donations 200 mL or more in the month before the trial or have plans for making a blood donation 200 mL or more during the trial period (9)Those who play intense sports and who are on a diet (10)Those who have smoking habits (11)Extremely irregular dietary patterns (12)Those who regularly use health foods (including supplements with antioxidant or blood flow improving effects) for the purpose of decreasing brain function or improving memory loss (13)Those who are taking medicines (antipsychotics, anxiolytics, etc.) that may affect the study (14)Those who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and designated quasi-drugs during the test period (15)Those who continuously take medicines (including OTC and prescription medicines) (16)Heavy drinkers, or those who can't stop drinking from the day before the test until the day (17)Those who have been pregnant or those who have a plan to become pregnant or breast feed during the study period (18)Those who are participating in or will be participating in other clinical trials at the start of this study, and those within 4 weeks after the end (19)Those who judged that examination responsible doctor is not appropriate for this study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Doctor's questions, Physiological test, Clinical examination, Adverse event | — |
Countries
Japan
Contacts
Public ContactMegumi Takahashi
Ryusendo Co., Ltd. Development Division
Outcome results
None listed